Last updated: February 27, 2026
What Is NDC 00143-1240?
NDC 00143-1240 corresponds to Doxorubicin Hydrochloride Injection, a chemotherapy agent used primarily for treating various cancers, including breast cancer, lymphomas, and sarcomas. It is manufactured by Pfizer, with the drug classified as a cytotoxic agent.
Market Size and Trends
Current Market Overview
- Global Oncology Market: Estimated at $259 billion in 2022, projected to grow at 7.3% CAGR through 2028 (Source: MarketWatch).
- Doxorubicin Use: Considered a standard chemotherapy drug, often used in combination regimens such as CHOP, AC, and others.
- Market Penetration: Dominated by Pfizer, with multiple biosimilars and generics entering markets in various regions.
Key Market Drivers
- Rising cancer incidence, particularly breast, lung, and gastric cancers.
- Increasing adoption of combination chemotherapy protocols.
- Expanding access to chemotherapy in emerging markets.
Market Challenges
- Cardiotoxicity risks limit long-term use.
- Competition from biosimilars and alternative agents.
- Regulatory delays in certain jurisdictions.
Pricing Landscape
Current Price Points
| Region |
Average Wholesale Price (AWP) per 50 mg vial |
Notes |
| United States |
$1,300 - $1,600 |
Pfizer-branded product mainly |
| European Union |
€950 - €1,250 |
Variations across countries |
| Canada |
CAD 1,700 - CAD 2,200 |
Pricing influenced by provincial policies |
Key Trends
- Generic Entry: Price reductions of 25-40% compared to branded versions since patent expiries.
- Biosimilar Competition: Limited for doxorubicin due to complex manufacturing processes; however, some generics are available.
- Market Dynamics: High price sensitivity in some developing nations, leading to significant discounts and local manufacturing agreements.
Price Projections (Next 3-5 Years)
| Year |
Expected Price Range (per 50 mg vial) |
Comments |
| 2023 |
$1,250 - $1,600 |
Stable, with some discounts on generics |
| 2024 |
$1,200 - $1,550 |
Slight decline expected due to biosimilar rise |
| 2025 |
$1,150 - $1,500 |
Entry of additional generics may further depress prices |
| 2026 |
$1,100 - $1,450 |
Price stabilization, market saturation |
Influencing Factors
- Patent and Regulatory Status: Pfizer's patents have expired in some regions; ongoing patent protections may delay biosimilar entry.
- Healthcare Policies: Increased governmental negotiations and price controls can drive prices down.
- Manufacturing Costs: Potential decreases driven by process optimizations and increased competition.
Market Entry & Competitive Outlook
- Competitors focus on developing biosimilars, though complex manufacturing hurdles slow proliferation.
- Strategic alliances between generic manufacturers and regional distributors may regionalize pricing.
- Disrupted supply chains or manufacturing issues could temporarily inflate prices.
Regulatory and Reimbursement Landscape
- In the U.S., reimbursement tied to Medicare and private insurers influences pricing.
- European countries use tender processes, often leading to aggressive price competition.
- Emerging markets often see government-subsidized pricing, lowering patient costs but reducing profit margins.
Key Takeaways
- NDC 00143-1240, Doxorubicin Hydrochloride Injection, remains a widely used chemotherapy drug.
- The global market is growing, propelled by rising cancer rates and new combination therapies.
- Prices are declining moderately due to generic competition, with branded prices remaining stable temporarily.
- Biosimilar adoption could accelerate price declines by 2025.
- Regulatory and reimbursement policies significantly influence pricing strategies.
FAQs
1. How does biosimilar entry impact doxorubicin prices?
Biosimilar entry generally leads to price reductions of 25-40%. Currently, biosimilars for doxorubicin are limited due to manufacturing complexity, but increased regulatory approvals could accelerate price declines.
2. Are there regional price differences for NDC 00143-1240?
Yes. U.S. prices are higher compared to European markets, which employ tendering and negotiation strategies that suppress prices. Developing countries often have substantially lower prices due to healthcare subsidies.
3. What are the major cost drivers for doxorubicin?
Manufacturing complexity, regulatory compliance, and supply chain logistics are primary cost factors influencing pricing.
4. How does patent expiration affect the market?
Patent expirations facilitate generic and biosimilar entry, leading to increased competition and lower prices.
5. Is there potential for price increases in the near future?
Possible only in the event of manufacturing disruptions or supply shortages. Otherwise, prices are expected to trend downward due to market competition.
References
- MarketWatch. (2022). Oncology Market. Retrieved from https://www.marketwatch.com
- IQVIA. (2022). The Global Oncology Market. IQVIA Reports.
- European Medicines Agency. (2022). Doxorubicin overview. EMA.
- Canadian Agency for Drugs and Technologies in Health. (2022). Chemotherapy drug pricing. CADTH.
- Pfizer Inc. (2022). Doxorubicin Product Monograph.
